Single-Arm Studies Can Have Adaptive Designs, Industry Tells FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent draft guidance on adaptive device trial designs is a good step, but it should be more inclusive of single-arm studies and not just randomized trials, AdvaMed says.
You may also be interested in...
Adaptive Study Design OK For Single-Arm Trials, FDA Says
A newly finalized guidance document offers the US agency’s take on how and when clinical trials can be modified midstream. It includes some revisions from a draft version, including more attention paid the possibility of adaptive single-arm trials.
Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.